Retrospective study of overall survival in patients with de novo metastatic hormone-sensitive prostate cancer

Overall survival in metastatic hormone-sensitive prostate cancer (mHSPC) has improved in clinical trials over the last 20 years. It is not clear whether new treatments have translated to improvements in survival rates in clinical practice. Retrospective analysis of the SEER database and the VHA database quantified trends in OS among patients with de novo (synchronous) mHSPC from 2000 to 2019. From the years 2000-2004 to the years 2015-2019, median OS increased from 23.0 months to 30.0 months in SEER (HR 0.80; 95% CI 0.77-0.82) and from 25.6 months to 30.9 months in VHA (0.91; 0.87-0.96). The improvement was more pronounced among patients with a diagnosis before age 70 years, but was also statistically significant among patients who were older at diagnosis. Among patients over 80 years of age at diagnosis, OS was poor, with little improvement over time.